Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | AHR | P35869 | 1/20 | 1.00 |
| ▸ | PLK1 | P53350 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502916 | 1.00 | KDM4E (1.00) | KDM4EAHRPLK1ALDH1A1TSHR | |
| SCHEMBL719242 | 0.88 | KDM4E (0.78) | KDM4EAHRPLK1ALDH1A1TSHR | |
| SCHEMBL4775716 | 0.83 | KDM4E (0.71) | KDM4EAHRPLK1ALDH1A1TSHR | |
| SCHEMBL6964091 | 0.83 | KDM4E (0.71) | KDM4EAHRPLK1ALDH1A1TSHR | |
| SCHEMBL1885241 | 0.83 | KDM4E (1.00) | KDM4EAHRALDH1A1MAPTNPC1 | |
| SCHEMBL23610617 | 0.83 | KDM4E (0.70) | KDM4EAHRPLK1ALDH1A1LMNA | |
| SCHEMBL8871762 | 0.82 | KDM4E (0.70) | KDM4EAHRPLK1ALDH1A1TSHR | |
| SCHEMBL27297336 | 0.82 | PLK1 (0.75) | KDM4EAHRPLK1ALDH1A1TSHR | |
| SCHEMBL4593787 | 0.82 | KDM4E (0.70) | KDM4EAHRPLK1ALDH1A1MAPT | |
| SCHEMBL21800976 | 0.82 | KDM4E (0.69) | KDM4EAHRPLK1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233174-A1 | BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-13 | — | — | WO | disclosed |
| EP-4615849-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615578-A1 | CYCLIC PYRIDINE DERIVATIVES AS CGAS INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| CN-120202206-A | Cyclic benzimidazole derivatives as cGAS inhibitors | 勃林格殷格翰国际有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240189315-A1 | Cyclic Pyridine Derivatives as cGAS Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2024-06-13 | — | — | US | disclosed |
| CN-113453762-B | Pentacyclic heterocyclic compounds | 卫材R&D管理有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-6596726-B1 | Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme | WARNER LAMBERT COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | disclosed |
| EP-0808318-B1 | TRICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS | ABBOTT LAB (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-0808318-A1 | TRICYCLIC SUBSTITUTED HEXAHYDROBENZ E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS | Abbott Laboratories (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5679683-A | USEFUL FOR TREATING CANCER, ARTHRITIS, PSORIASIS, VASCULAR RESTENOSIS AND ANGIOGENESIS | WARNER-LAMBERT COMPANY (US) | 1997-10-21 | — | — | US | disclosed |
| US-5597823-A | TREATING BENIGN PROSTATIC HYPERPLASIA | ABBOTT LABORATORIES (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0741711-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019970-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| CN-1007153-B | PREPN. OF BENZOTHIOPHENES AND BENZOFURANS HAVING ANTIALLERGY ACTIVITY | WARNER LAMBERT CO (US) | 1990-03-14 | — | — | CN | disclosed |
| CN-85109587-A | Have the new benzothiophene kind of antiallergic activity and the preparation method of benzofuran compounds | — | 1986-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885AHR 451/4885PLK1 3682/4885 |
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | CGAS, STING1, IFNAR1 | KDM4E 2028/4885AHR 2851/4885PLK1 1282/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885AHR 451/4885PLK1 3682/4885 |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | CDK1, CHEK1, ABL1 | KDM4E 1527/4885AHR 3045/4885PLK1 27/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | KDM4E 4059/4885AHR 3627/4885PLK1 605/4885 |
| US-20240189315-A1 | Cyclic Pyridine Derivatives as cGAS Inhibitors | CGAS, STING1, IRF3 | KDM4E 1598/4885AHR 2189/4885PLK1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.